Drugs / pNGVL4aCRTE6E7L2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03913117 | Jul 2023 → Dec 2027 expected | cervical adenosquamous carcinoma, cervical squamous intraepithelial neoplasia | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 1 | NCT04131413 | Sep 2020 → Dec 2027 expected | cervical intraepithelial neoplasia grade 2/3 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pNGVL4aCRTE6E7L2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04131413 ↗ |
| Modality | Vaccine | “pNGVL4aCRTE6E7L2 DNA vaccine” NCT03913117 ↗ |
| Route | Intramuscular | “administered by intramuscular (IM) injection” NCT04131413 ↗ |